ArticleCell reports. Medicine2024
β-resorcylic acid released by Limosilactobacillus reuteri protects against cisplatin-induced ovarian toxicity and infertility.
Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Indole-3-carboxaldehyde fromGut microbes · 2026Article
- Growth Hormone Reverses Cisplatin-Induced Ovarian Reserve Depletion in Mice: Transcriptomic Elucidation of Mitochondrial Metabolic Reprogramming and Protein Synthesis Regulation.FASEB bioAdvances · 2026Article
- Proanthocyanidins Attenuate Cisplatin-Induced Acute Kidney Injury and are Associated With Reshaping Gut Microbiota and Restoring Redox Homeostasis.Molecular nutrition & food research · 2026Article
- Article
- Maternal and infant gut microbiome.iMeta · 2026Review
- Lactobacillus salivarius li01 alleviates premature ovarian insufficiency via gut microbiota-mediated modulation of tryptophan metabolism.NPJ science of food · 2026Article
- Pathogenic mechanisms and comprehensive therapeutic strategies of ovarian aging: targeting gut microbiota.Frontiers in microbiology · 2026Review
- Gut microbiota-derived butyrate and the SIRT1/FoxO1 axis: epigenetic-metabolic regulation of ovarian function in premature ovarian insufficiency-a comprehensive review.Frontiers in microbiology · 2026Review
- Microbiota-Host Interactions in Perimenopausal Syndrome: Mechanisms and Therapeutic Strategies (Review).International journal of women's health · 2026Review
- The microbiota extends the reproductive lifespan of mice by safeguarding the ovarian reserve.Cell host & microbe · 2025Article
- Article
- From gut to gamete: how the microbiome influences fertility and preconception health.Microbiome · 2025Review
- Development of a predictive framework for ovarian reserve decline based on pelvic microbiota dysbiosis.The EPMA journal · 2025Article
- Dominant follicle-targeted nanocarriers for GH delivery to alleviate premature ovarian insufficiency.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy-induced premature ovarian insufficiency (CIPOI) triggers gonadotoxicity in women undergoing cancer treatment, leading to loss of ovarian reserves and subfertility, with no effective therapies available. In our study, fecal microbiota transplantation in a cisplatin-induced POI mouse model reveals that a dysbiotic gut microbiome negatively impacts ovarian health in CIPOI. Multi-omics analyses show a significant decrease in Limosilactobacillus reuteri and its catabolite, β-resorcylic acid , in the CIPOI group in comparison to healthy controls. Supplementation with L. reuteri or β-RA mitigates cisplatin-induced hormonal disruptions, morphological damages, and reductions in follicular reserve. Most importantly, β-RA pre-treatment effectively preserves oocyte function, embryonic development, and fetus health, thereby protecting against chemotherapy-induced subfertility. Our results provide evidence that β-RA suppresses the nuclear accumulation of sex-determining region Y-box 7, which in turn reduces Bcl-2-associated X activation and inhibits granulosa cell apoptosis. These findings highlight the therapeutic potential of targeting the gut-ovary axis for fertility preservation in CIPOI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.